Clearmind Medicine Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CMND | SILO | QNTM | JUNS | ENVB | SPRC | |
|---|---|---|---|---|---|---|
| Market cap | 3.32M | 3.06M | 18.13M | 4.01M | 6.58M | 2.37M |
| P/E (TTM) | — | — | — | — | — | 0.0 |
| Forward P/E | — | -2.1 | -0.4 | 50.7 | -1.0 | — |
| Price/book | 0.1 | 0.3 | 2.7 | -5.5 | 0.7 | 0.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −99.78% | −84.39% | −80.65% | −97.38% | −81.30% | −85.69% |
| Today | −0.61% | +1.36% | −4.08% | +6.67% | +1.38% | −9.33% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CMND news ›Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic ... Clearmind Medicine Receives Yale IRB…
SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine
SciSparc (SPRC) announced that NeuroThera Labs highlighted the expansion of the U.S. intellectual property, IP, portfolio through its ongoing co... SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine SciSparc (SPRC)…
Return on assets % of Clearmind Medicine Inc. – MUN:CWY1
Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use…
Clearmind Medicine says Japan published dyskinesia patent application
The company says its 3-MMC claims cover dyskinesia treatment alone and with PEA, but gave no publication number or grant timetable. Japan has published a patent application for a proposed dyskinesia treatment, according to an Oct. 8…
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
Company completed treatment in four additional participate at its Israel clinical site This milestone reflects continued positive progress and strong momentum in the multinational, multicenter study, which is designed to evaluate the…
Clearmind Medicine Inc. : Insider Transactions
Follow insider transactions on Clearmind Medicine Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Clearmind Medicine Inc. Biotechnology & Medical Research Latest…
All Transcripts on Clearmind Medicine Inc. (CMND)
Find all the latest transcripts on Clearmind Medicine Inc. Transcripts Clearmind Medicine Inc. Biotechnology & Medical Research All financial news and data tailored to specific country editions
Clearmind Medicine Inc.: Relative Strength Chart - Stock Nasdaq
Compare Clearmind Medicine Inc. with the company of your choice via a Relative Strength chart. Real-time CMND price, Nasdaq stock exchange Relative Strength Chart Clearmind Medicine Inc. Biotechnology & Medical Research All financial news…
Clearmind Medicine Inc.: News in other languages | CMND | CA1850537095
Clearmind Medicine Inc.: News, information and stories for Clearmind Medicine Inc. | Nasdaq: CMND | Nasdaq Other languages Clearmind Medicine Inc. Biotechnology & Medical Research All financial news and data tailored to specific country…
Clearmind Medicine Advances MDMA-N-Acylethanolamines Patent Application For Treatment Of PTSD
Clearmind Medicine Inc. announced an advancement of its IP portfolio with the publication in the United States of its patent application covering a novel combination of... announced an advancement of its IP portfolio with the publication…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com9
-
markets.businessinsider.com4
-
stocktitan.net4
-
tradingview.com2
-
markets.financialcontent.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.